Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cathy Eng

Showing results (201-210 of 315) with videos related to

Pageof 32
Sort By:
British Journal of Cancer|August 1, 2020
Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancerKanwal Raghav, John P Shen, Alexandre A Jácome, et al.
Oncotarget|October 28, 2016
Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancerChang Liu, Cathy Eng, Jianjun Shen, et al.
Cancer|September 17, 2013
Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canalCathy Eng, George J Chang, Y Nancy You, et al.
Cancer Medicine|October 18, 2013
Metformin use and improved response to therapy in rectal cancerHeath D Skinner, Christopher H Crane, Christopher R Garrett, et al.
International Journal of Radiation Oncology, Biology, Physics|January 17, 2009
Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical courseMichael P Herman, Scott Kopetz, Priya R Bhosale, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 24, 2013
Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trialYing Guo, Desiree Jones, J Lynn Palmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Neoadjuvant treatment response as an early response indicator for patients with rectal cancerIn Ja Park, Y Nancy You, Atin Agarwal, et al.
Future Oncology (London, England)|May 20, 2025
The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summaryScott Kopetz, Takayuki Yoshino, Eric Van Cutsem, et al.
Nature Medicine|January 25, 2025
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trialScott Kopetz, Takayuki Yoshino, Eric Van Cutsem, et al.
Annals of Surgical Oncology|May 29, 2009
Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin CLaura A Lambert, Terri S Armstrong, J Jack Lee, et al.
Pageof 32

Showing results (201-210 of 315) with videos related to

Sort By:
Pageof 32
British Journal of Cancer|August 1, 2020
Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancerKanwal Raghav, John P Shen, Alexandre A Jácome, et al.
Oncotarget|October 28, 2016
Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancerChang Liu, Cathy Eng, Jianjun Shen, et al.
Cancer|September 17, 2013
Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canalCathy Eng, George J Chang, Y Nancy You, et al.
Cancer Medicine|October 18, 2013
Metformin use and improved response to therapy in rectal cancerHeath D Skinner, Christopher H Crane, Christopher R Garrett, et al.
International Journal of Radiation Oncology, Biology, Physics|January 17, 2009
Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical courseMichael P Herman, Scott Kopetz, Priya R Bhosale, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 24, 2013
Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trialYing Guo, Desiree Jones, J Lynn Palmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Neoadjuvant treatment response as an early response indicator for patients with rectal cancerIn Ja Park, Y Nancy You, Atin Agarwal, et al.
Future Oncology (London, England)|May 20, 2025
The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: a plain language summaryScott Kopetz, Takayuki Yoshino, Eric Van Cutsem, et al.
Nature Medicine|January 25, 2025
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trialScott Kopetz, Takayuki Yoshino, Eric Van Cutsem, et al.
Annals of Surgical Oncology|May 29, 2009
Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin CLaura A Lambert, Terri S Armstrong, J Jack Lee, et al.
Pageof 32